alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<PAGE>



                                                                     EXHIBIT 3.4

                           CERTIFICATE OF AMENDMENT OF
                          CERTIFICATE OF INCORPORATION
                                       OF
                          QUICKRESPONSE SERVICES, INC.
                             a Delaware corporation

                           (pursuant to Section 242 of
                      the Delaware General Corporation Law)


     The undersigned, H. Lynn Hazlett, HEREBY CERTIFIES AS FOLLOWS:

     FIRST: The name of the corporation (hereinafter called the "Corporation")
is QuickResponse Services, Inc.

     SECOND: The Certificate of Incorporation of said Corporation, which was
originally incorporated in Delaware on June 23, 1997 under the name
QuickResponse Delaware, Inc., and whose name was corrected by Certificate of
Correction on October 21, 1997 to the Corporation's current name of
QuickResponse Services, Inc., is hereby amended by striking out Article First
thereof and by substituting in lieu of said Article First, the following new
Article First:

          "FIRST: The name of this corporation is QRS Corporation."

     THIRD: The amendment of the Certificate of Incorporation of the Corporation
herein certified has been duly adopted in accordance with the provisions of
Section 242 of the General Corporation Law of the State of Delaware.


     IN WITNESS WHEREOF, the undersigned has executed this Certificate of
Amendment of Certificate of Incorporation this 8th day of May, 1998.



                                        /S/ H. LYNN HAZLETT        
                                        ----------------------------------------
                                        H. Lynn Hazlett, Chief Executive Officer
```

[111th Congress Public Law 307]
[From the U.S. Government Printing Office]

[[Page 124 STAT. 3282]]

Public Law 111-307
111th Congress

                                 An Act

 
  To amend section 42 of title 18, United States Code, to prohibit the 
 importation and shipment of certain species of carp. <<NOTE: Dec. 14, 
                          2010 -  [S. 1421]>> 

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress <<NOTE: Asian Carp Prevention and 
Control Act.>> asssembled,
SECTION 1. SHORT <<NOTE: 18 USC 1 note.>> TITLE.

    This Act may be cited as the ``Asian Carp Prevention and Control 
Act''.
SEC. 2. ADDITION OF SPECIES OF CARP TO THE LIST OF INJURIOUS 
                    SPECIES THAT ARE PROHIBITED FROM BEING 
                    IMPORTED OR SHIPPED.

    Section 42(a)(1) of title 18, United States Code, is amended by 
inserting ``of the bighead carp of the species Hypophthalmichthys 
nobilis;'' after ``Dreissena polymorpha;''.

    Approved December 14, 2010.

LEGISLATIVE HISTORY--S. 1421:
---------------------------------------------------------------------------

SENATE REPORTS: No. 111-181 (Comm. on Environment and Public Works).
CONGRESSIONAL RECORD, Vol. 156 (2010):
            Nov. 17, considered and passed Senate.
            Dec. 1, considered and passed House.

                                  <all>
```
#### Leroy Carlton HARRIS, Appellant, v. Maria PEREZ, a minor, by her mother and next friend Camille Perez, Appellee.

No. 69-975.

District Court of Appeal of Florida, Third District.

April 8, 1970.

PER CURIAM.

Appeal dismissed.
2005 Decisions

Opinions of the United

States Court of Appeals

for the Third Circuit

12-27-2005

USA v. Rodriguez

Precedential or Non-Precedential: Non-Precedential

Docket No. 04-1801

Follow this and additional works at: http://digitalcommons.law.villanova.edu/thirdcircuit_2005

This decision is brought to you for free and open access by the Opinions of the United States Court of Appeals for the Third Circuit at Villanova

University School of Law Digital Repository. It has been accepted for inclusion in 2005 Decisions by an authorized administrator of Villanova

University School of Law Digital Repository. For more information, please contact Benjamin.Carlson@law.villanova.edu.

Recommended Citation

"USA v. Rodriguez" (2005). 2005 Decisions. Paper 49.

http://digitalcommons.law.villanova.edu/thirdcircuit_2005/49
UNITED STATES COURT OF APPEALS FOR THE THIRD CIRCUIT

 October 18, 2005

No. 04-1801

United States of America

vs.

Miguel Rodriguez, Appellant

(District of New Jersey Criminal No. 01-cr-00021-5)

PRESENT: ROTH, McKEE and FISHER, Circuit Judges.

Letter dated 10/17/05 from counsel for Appellee, which the Court may wish to

construe as a motion to amend the opinion.

 

Answer due 10/31/05 Tonya Wyche 267-299-4938

Opinion & Judgment entered 10/14/05 Case Manager

Mandate due to issue 11/7/05

 O R D E R 

The foregoing motion to amend the opinion is granted.

By the Court,

/s/ D. Michael Fisher 

Circuit Judge

Dated: December 27, 2005

tyw/cc: Mitchell Ignatoff, Esq.

 Mark E. Coyne, Esq.

 George S. Leone, Esq.
<TABLE> <S> <C>


<ARTICLE>                     5
       
<S>                             <C>
<PERIOD-TYPE>                   12-MOS                  
<FISCAL-YEAR-END>                           DEC-31-1998 
<PERIOD-END>                                DEC-31-1998 
<CASH>                                      101,475,185 
<SECURITIES>                                  4,555,343 
<RECEIVABLES>                                 7,888,903 
<ALLOWANCES>                                   (250,879)
<INVENTORY>                                   1,861,372 
<CURRENT-ASSETS>                              1,210,778 
<PP&E>                                       21,471,147 
<DEPRECIATION>                              (15,381,974)
<TOTAL-ASSETS>                              124,607,662 
<CURRENT-LIABILITIES>                        18,785,438 
<BONDS>                                     115,000,000 
<PREFERRED-MANDATORY>                                 0 
<PREFERRED>                                           0 
<COMMON>                                        134,367 
<OTHER-SE>                                  162,778,408 
<TOTAL-LIABILITY-AND-EQUITY>                124,607,662 
<SALES>                                       8,276,105 
<TOTAL-REVENUES>                             39,317,090 
<CGS>                                         7,105,515 
<TOTAL-COSTS>                                 7,105,515 
<OTHER-EXPENSES>                             35,947,703 
<LOSS-PROVISION>                                      0 
<INTEREST-EXPENSE>                             (126,904)
<INCOME-PRETAX>                              (2,760,711)
<INCOME-TAX>                                          0 
<INCOME-CONTINUING>                          (2,760,711)
<DISCONTINUED>                                        0 
<EXTRAORDINARY>                                       0 
<CHANGES>                                             0 
<NET-INCOME>                                 (2,760,711)
<EPS-PRIMARY>                                      (.21)
<EPS-DILUTED>                                      (.21)
                                


</TABLE>
##### 





EXHIBIT 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of ProxyMed, Inc. (the Company) on
Form 10-K for the period ending December 31, 2003 as filed with the Securities
and Exchange Commission on the date hereof (the Report), I, Gregory J.
Eisenhauer, Chief Financial Officer of the Company, certify, pursuant to 18
U.S.C. ss.1350, as adopted pursuant to ss.906 of the Sarbanes-Oxley Act of
2002, that:

(1) The Report fully complies with the requirements of section 13(a) or
15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all
material respects, the financial condition and result of operations of the
Company.

/s/ GREGORY J. EISENHAUER, CFA

---




A signed original of this written statement required by Section 906 has been
provided to ProxyMed, Inc. and will be retained by ProxyMed, Inc. and furnished
to the Securities and Exchange Commission or its staff upon request.
<TABLE> <S> <C>

<PAGE>

<ARTICLE> 5
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          NOV-30-2000
<PERIOD-START>                             DEC-01-1999
<PERIOD-END>                               AUG-31-2000
<CASH>                                             809
<SECURITIES>                                         0
<RECEIVABLES>                                   30,545
<ALLOWANCES>                                       592
<INVENTORY>                                     44,007
<CURRENT-ASSETS>                                76,983
<PP&E>                                         101,105
<DEPRECIATION>                                  53,339
<TOTAL-ASSETS>                                 132,035
<CURRENT-LIABILITIES>                           12,088
<BONDS>                                         12,500
<PREFERRED-MANDATORY>                           10,129<F1>
<PREFERRED>                                          0
<COMMON>                                         2,418
<OTHER-SE>                                      92,607
<TOTAL-LIABILITY-AND-EQUITY>                   132,035
<SALES>                                        183,355
<TOTAL-REVENUES>                               183,355
<CGS>                                          134,606
<TOTAL-COSTS>                                  164,904
<OTHER-EXPENSES>                                  (47)
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                 18,498
<INCOME-TAX>                                     6,766
<INCOME-CONTINUING>                             11,732
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    11,732
<EPS-BASIC>                                       1.54
<EPS-DILUTED>                                     1.54
<FN>
<F1>Represents Common Stock held by ESOP
</FN>


</TABLE>
Exhibit 10.5

Translated From Japanese

Please confirm conditions below.

                                Issue Conditions

1. Title of bonds:         Global Hotline KK
                           The first unsecured bond (Mizuho bank KK Guarantee
                           and it is limited for accredited institution)

2. Total issuing:          150,000,000 yen

3. Redemption amount per
   corporate bond          10,000,000 yen

4. Issue date              2007/7/17

5. Interest payment date   The end of Jun. and the end of Dec. every year (twice
                           a year)

6. Bond Maturity           5 years

7. Redemption              Controlled amortization

8. Amount of controlled
   amortization            1,000,000 yen

9. Redemption Due Date     The first date is the end of Dec/2007

                           Redeem 1,500,000 yen in the end of Jun. and Dec.
                           every year

                           The last date is 2007/6/29 to redeem the rest amount
                           1,500,000 yen

10. Interest               1.640 %

11. Amount due             100 yen per 100yen of bond

12. Guarantor              Mizuho Bank
                           Portion: 100%
                           (Guarantor fee 0.650% per year)

13. Fiscal agent           Mizuho Bank KK

14. Paying and issuing
    agent                  Mizuho Bank KK

15. Full amount Guarantor  Mizuho Bank KK

16. Directors Meeting date (Bond issued date)         2007/7/6

17. Estimated contract certification execution date   2007/7/9

                                     - 1 -
<PAGE>

Commission and payment due

1. Administrative service commission  3,000,000 yen (issue date)

2. Paying commission                  375,000 yen (amount of issue x 0.250%)

3.                                    (issue date)

4. Newly issued recording commission  13,300 yen (issue date)

5. Principal payment commission       10 sen per 100 yen of principal
                                      (redemption date)

6. Interest payment commission        20 sen per 100 yen of payment
                                      (interest payment date)

7. Retire bond commission             10 sen per 100 yen of principal
                                      (Retire date)

                                      - 2 -
#### Marion W. BRIGHAM, Appellant, v. Marian Alice MURRAY, et al., Appellees.

No. 69-16.

District Court of Appeal of Florida. Third District.

Dec. 23, 1969.

PER CURIAM.

Appeal dismissed.
[Federal Register Volume 62, Number 23 (Tuesday, February 4, 1997)]
[Notices]
[Page 5240]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-2728]



[[Page 5240]]

-----------------------------------------------------------------------


DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Heart, Lung, and Blood Institute; Notice of Closed 
Meeting

    Pursuant to Section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of the following 
Initial Review Group (IRG) meeting:

    Name if IRG: Heart, Lung, and Blood Program Project Review 
Committee.
    Date: March 27, 1997.
    Time: 8:00 a.m.
    Place: Holiday Inn Chevy Chase, 5520 Wisconsin Avenue, Chevy 
Chase, Maryland 20815.
    Contact Person: Dr. Jeffrey H. Hurst, Scientific Review 
Administrator, NHLBI/Review Branch, 6701 Rockledge Drive, Rm. 7208, 
Bethesda, Maryland 20892, (301) 435-0303.
    Purpose/Agenda: To review and evaluate program project grant 
applications.
    The meeting will be closed in accordance with the provisions set 
forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. 
Applications and the discussions could reveal confidential trade 
secrets or commercial property such as patentable material and 
personal information concerning individuals associated with the 
applications, the disclosure of which would constitute a clearly 
unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Programs Nos. 93.837, Heart 
and Vascular Diseases Research; 93.838, Lung Diseases Research; and 
93.839, Blood Diseases and Resources Research, National Institutes 
of Health.)

    Dated: January 29, 1997.
Paula N. Hayes,
Acting Committee Management Officer, NIH.
[FR Doc. 97-2728 Filed 2-3-97; 8:45 am]
BILLING CODE 4140-01-M
[Federal Register Volume 62, Number 195 (Wednesday, October 8, 1997)]
[Notices]
[Page 52616]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-26672]


-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Surface Transportation Board
[STB Finance Docket No. 33408]


Gateway Western Railway Company--Lease Exemption--The Burlington 
Northern and Santa Fe Railway Company

AGENCY: Surface Transportation Board, DOT.

ACTION: Notice of exemption.

-----------------------------------------------------------------------

SUMMARY: Under 49 U.S.C. 10502, the Board exempts from the requirements 
of 49 U.S.C. 11323-25 the lease by Gateway Western Railway Company of 
The Burlington Northern and Santa Fe Railway Company's Coburg Line, 
extending a distance of 5.45 miles between milepost 0.0 at the 
Sheffield interlocking and milepost 5.45 near BV Junction, in Kansas 
City, Jackson County, MO, subject to standard labor protective 
conditions.

DATES: The exemption will be effective November 7, 1997. Petitions to 
stay must be filed by October 23, 1997. Petitions to reopen must be 
filed by November 3, 1997.

ADDRESSES: An original and 10 copies of all pleadings referring to STB 
Finance Docket No. 33408 must be filed with the Surface Transportation 
Board, Office of the Secretary, Case Control Unit, 1925 K Street, N.W., 
Washington, DC 20423-0001; in addition, a copy of all pleadings must be 
served on petitioner's representative: William C. Sippel, Oppenheimer 
Wolff & Donnelly, Two Prudential Plaza, 45th Floor, 180 North Stetson 
Avenue, Chicago, IL 60601.

FOR FURTHER INFORMATION CONTACT: Beryl Gordon (202) 565-1600. [TDD for 
the hearing impaired: (202) 565-1695.]

SUPPLEMENTARY INFORMATION: Additional information is contained in the 
Board's decision. To purchase a copy of the full decision, write to, 
call or pick up in person from: DC NEWS & DATA INC., 1925 K Street, 
N.W., Suite 210, Washington DC 20006. Telephone: (202) 289-4357. 
[Assistance for the hearing impaired is available through TDD services 
(202) 565-1695.]

    Decided: September 29, 1997.

    By the Board, Chairman Morgan and Vice Chairman Owen.
Vernon A. Williams,
Secretary.
[FR Doc. 97-26672 Filed 10-7-97; 8:45 am]
BILLING CODE 4915-00-P
QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 4.2    
  


 
  AMENDMENT OF ARTICLES OF INCORPORATION
  OF
  MEDWAVE, INC.    
  


        The Articles of Incorporation of Medwave, Inc. have been amended in the following respects: 



        1.
A new Article 8 has been added to read as follows: 


 
 

"ARTICLE 8—REMOVAL OF DIRECTORS    
  


        8.1) If
any director or directors are proposed to be removed from office, with or without cause, by action of the shareholders, the affirmative vote of shareholders holding
at least 75% of the voting power of all shares entitled to vote shall be required to remove any or all of the directors from office, with or without cause." 


        2.    A
new Article 9 has been added to read as follows: 


 
 

"ARTICLE 9—AMENDMENT OF BYLAWS AND
  ARTICLES 8 AND 9 OF ARTICLES OF INCORPORATION    
  



        9.1)    Amendment of Bylaws.    Sections 3.2 and 3.3 of the Bylaws fixing the number of directors or their
classifications, qualifications or terms of office, or prescribing procedures for removing directors or filling vacancies on the Board, may be amended or repealed by shareholders only by the
affirmative vote of the holders of at least 75% of the voting power of all shares entitled to vote. 


        9.2)    Amendment of Articles 8 and 9 of Articles of Incorporation.    Notwithstanding any other provisions of these
Articles of Incorporation or the Bylaws of the corporation or the fact that a lesser percentage may be specified by law, these Articles of Incorporation or the Bylaws of the corporation, the
affirmative vote of the holders of at least 75% of the voting power of all shares entitled to vote shall be required to amend or repeal all or any portion of Article 8 and this Article 9
or to adopt, amend or repeal any other provision of the Articles of Incorporation or Bylaws of the corporation so as to be inconsistent with or to contravene Article 8 or this
Article 9." 




        The
foregoing amendments have been approved pursuant to Chapter 302A, Minnesota Statutes. 









QuickLinks



Exhibit 4.2


AMENDMENT OF ARTICLES OF INCORPORATION OF MEDWAVE, INC.

"ARTICLE 8—REMOVAL OF DIRECTORS

"ARTICLE 9—AMENDMENT OF BYLAWS AND ARTICLES 8 AND 9 OF ARTICLES OF INCORPORATION
Exhibit

10.3




 




MODIFICATION TO PROMISSORY NOTE




 




WHEREAS, on July 3, 1995, Lee Pharmaceuticals

(“maker”) and Sass DiSalvo (“Holder”) entered into an agreement (“Note”)

whereby Lee Pharmaceuticals was to pay to Sass DiSalvo the sum of Fifty

Thousand Dollars; and




 




WHEREAS, on July 6, 1996, the parties thereto modified

said Note to extend the maturity date from July 6, 1996, until December 8,

1997, ( a copy of said Modification to Promissory Note is attached for

reference as Exhibit A); and




 




WHEREAS, on December 8, 1997, the parties thereto

modified said Note to extend the maturity date from December 8, 1997, until

December 1, 1998, (a copy of said Modification to Promissory Note is attached

for reference as Exhibit B); and




 




WHEREAS, on December 1, 1998, the parties thereto

modified said Note to extend the maturity date from December 1, 1998, until

June 30, 1999, (a copy of said Modification to Promissory Note is attached for

reference as Exhibit C); and




 




WHEREAS, on June 30, 1999, the parties thereto

modified said Note to extend the maturity date from June 30, 1999, until June

30, 2000, (a copy of said Modification to Promissory Note is attached for

reference as Exhibit D); and




 




WHEREAS, on June 30, 2000, the parties thereto

modified said Note to extend the maturity date from June 30, 2000, until

December 1, 2001, (a copy of said Modification to Promissory Note is attached

for reference as Exhibit E); and




 




WHEREAS, on December 1, 2001, the parties hereto

modified said Note to extend the maturity date from December 1, 2001, until

December 1, 2002, (a copy of said Modification to Promissory Note is attached

for reference as Exhibit F); and




 




WHEREAS, the parties thereto now desire to further

modify said Note and Modification;




 




NOW, THEREFORE, the parties modify said Note and

Modification as follows:




 




1.             The

maturity date of the Note is extended from December 1, 2002, until December 1,

2003.




 




2.             All

other terms and conditions of the Note remain the same.




 




Date this 27th day of November, 2002




 




 




	

   


  	

  /s/ RONALD G. LEE


  
	

   


  	

  Lee Pharmaceuticals


  





 





























 




	

   


  	

  By:  Ronald

  G. Lee, President


  
	

   


  	

   


  
	

   


  	

  /s/ SASS DI SALVO


  
	

   


  	

  Sass DiSalvo


  





 




2